Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus etoposide and platinum as first-line therapy for extensive-stage esophageal small cell carcinoma
ChiCTR2400093532Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Dec 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab and etoposide in small cell carcinoma of the esophagus (SCEC), sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
adebrelimabetoposide
03
Conditions
small cell carcinoma of the esophagus (SCEC)
Beyond the preview
Go deeper on ChiCTR2400093532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093532.